McLeod DG - Search Results

1

Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.

Moul JW, Bettencourt MC, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Bauer JJ. Moul JW, et al. Among authors: mcleod dg. Surgery. 1996 Aug;120(2):159-66; discussion 166-7. doi: 10.1016/s0039-6060(96)80283-2. Surgery. 1996. PMID: 8751578

2

Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.

Merseburger AS, Kuczyk MA, Serth J, Bokemeyer C, Young DY, Sun L, Connelly RR, McLeod DG, Mostofi FK, Srivastava SK, Stenzl A, Moul JW, Sesterhenn IA. Merseburger AS, et al. Among authors: mcleod dg. Oncol Rep. 2003 Jan-Feb;10(1):223-8. Oncol Rep. 2003. PMID: 12469173

3

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG. Whitman EJ, et al. Among authors: mcleod dg. J Urol. 2008 Nov;180(5):1975-8; discussion 1978-9. doi: 10.1016/j.juro.2008.07.060. Epub 2008 Sep 17. J Urol. 2008. PMID: 18801539

4

Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression.

Gesztes W, Schafer C, Young D, Fox J, Jiang J, Chen Y, Kuo HC, Mwamukonda KB, Dobi A, Burke AP, Moul JW, McLeod DG, Rosner IL, Petrovics G, Tan SH, Cullen J, Srivastava S, Sesterhenn IA. Gesztes W, et al. Among authors: mcleod dg. Sci Rep. 2022 Mar 30;12(1):5404. doi: 10.1038/s41598-022-08826-5. Sci Rep. 2022. PMID: 35354846 Free PMC article.

5

Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man.

Heidenberg HB, Moul JW, Mostofi FK, McLeod DG. Heidenberg HB, et al. Among authors: mcleod dg. J Urol. 1994 Sep;152(3):966-7. doi: 10.1016/s0022-5347(17)32626-5. J Urol. 1994. PMID: 8051769

6

Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting.

Moul JW, Douglas TH, McCarthy WF, McLeod DG. Moul JW, et al. Among authors: mcleod dg. J Urol. 1996 May;155(5):1667-73. J Urol. 1996. PMID: 8627850 Clinical Trial.

7

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.

Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Bettencourt MC, et al. Among authors: mcleod dg. J Urol. 1996 Sep;156(3):1064-8. J Urol. 1996. PMID: 8709308

8

Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.

Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Bauer JJ, et al. Among authors: mcleod dg. J Urol. 1996 Oct;156(4):1511-6. J Urol. 1996. PMID: 8808919

9

The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?

Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. Heidenberg HB, et al. Among authors: mcleod dg. Urology. 1996 Dec;48(6):971-9. doi: 10.1016/s0090-4295(96)00365-2. Urology. 1996. PMID: 8973691 Review. No abstract available.

10

Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy.

Bauer JJ, Connelly RR, Sesterhenn IA, Bettencourt MC, McLeod DG, Srivastava S, Moul JW. Bauer JJ, et al. Among authors: mcleod dg. Cancer. 1997 Mar 1;79(5):952-62. Cancer. 1997. PMID: 9041158

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

277 results

Search Page